GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Shiller PE Ratio

Traws Pharma (FRA:0T2) Shiller PE Ratio : (As of May. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Traws Pharma Shiller PE Ratio Historical Data

The historical data trend for Traws Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Shiller PE Ratio Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Traws Pharma's Shiller PE Ratio

For the Biotechnology subindustry, Traws Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Shiller PE Ratio falls into.



Traws Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Traws Pharma's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Traws Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.183/129.4194*129.4194
=-0.183

Current CPI (Dec. 2023) = 129.4194.

Traws Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -21,228.798 99.695 -27,558.374
201406 -19,126.506 100.560 -24,615.685
201409 -18,070.867 100.428 -23,287.583
201412 -16,969.932 99.070 -22,168.619
201503 -17,775.173 99.621 -23,092.018
201506 -12,419.203 100.684 -15,963.682
201509 -7,818.409 100.392 -10,079.078
201512 5,607.750 99.792 7,272.614
201603 -8,031.371 100.470 -10,345.487
201606 -5,887.261 101.688 -7,492.772
201609 -872.053 101.861 -1,107.986
201612 -2,578.086 101.863 -3,275.530
201703 -3,881.363 102.862 -4,883.462
201706 -871.074 103.349 -1,090.807
201709 -2,000.998 104.136 -2,486.834
201712 -1,669.281 104.011 -2,077.060
201803 -919.666 105.290 -1,130.432
201806 -211.858 106.317 -257.895
201809 -181.254 106.507 -220.247
201812 -168.107 105.998 -205.252
201903 -256.869 107.251 -309.964
201906 -119.474 108.070 -143.077
201909 -153.223 108.329 -183.053
201912 -10.469 108.420 -12.497
202003 -6.109 108.902 -7.260
202006 -0.577 108.767 -0.687
202009 -0.441 109.815 -0.520
202012 -0.427 109.897 -0.503
202103 -0.269 111.754 -0.312
202106 -0.224 114.631 -0.253
202109 -0.187 115.734 -0.209
202112 -0.142 117.630 -0.156
202203 -0.182 121.301 -0.194
202206 -0.180 125.017 -0.186
202209 -0.263 125.227 -0.272
202212 -0.245 125.222 -0.253
202303 -0.262 127.348 -0.266
202306 -0.185 128.729 -0.186
202309 -0.216 129.860 -0.215
202312 -0.183 129.419 -0.183

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Traws Pharma  (FRA:0T2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Traws Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (FRA:0T2) Business Description

Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines